Literature DB >> 18250609

The manifesto A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) study group one year later: what to keep and what to amend?

A Colao, E Ghigo.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 18250609     DOI： 10.1007/bf03349235

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  27 in total

Review 1.  Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.

Authors:  John S Bevan
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

2.  Consensus statement: medical management of acromegaly.

Authors:  S Melmed; F Casanueva; F Cavagnini; P Chanson; L A Frohman; R Gaillard; E Ghigo; K Ho; P Jaquet; D Kleinberg; S Lamberts; E Laws; G Lombardi; M C Sheppard; M Thorner; M L Vance; J A H Wass; A Giustina
Journal:  Eur J Endocrinol       Date:  2005-12       Impact factor: 6.664

3.  Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

Authors:  Renzo Zanettini; Angelo Antonini; Gemma Gatto; Rosa Gentile; Silvana Tesei; Gianni Pezzoli
Journal:  N Engl J Med       Date:  2007-01-04       Impact factor: 91.245

Review 4.  Pegvisomant in acromegaly: why, when, how.

Authors:  A Colao; G Arnaldi; P Beck-Peccoz; S Cannavò; R Cozzi; E degli Uberti; L De Marinis; E De Menis; D Ferone; V Gasco; A Giustina; S Grottoli; G Lombardi; P Maffei; E Martino; F Minuto; R Pivonello; E Ghigo
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

5.  Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.

Authors:  Annamaria Colao; Roberto Attanasio; Rosario Pivonello; Paolo Cappabianca; Luigi M Cavallo; Giovanni Lasio; Alessandro Lodrini; Gaetano Lombardi; Renato Cozzi
Journal:  J Clin Endocrinol Metab       Date:  2005-11-01       Impact factor: 5.958

6.  Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly.

Authors:  Annamaria Colao; Rosario Pivonello; Renata S Auriemma; Mariano Galdiero; Silvia Savastano; Gaetano Lombardi
Journal:  Eur J Endocrinol       Date:  2007-11       Impact factor: 6.664

7.  Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study.

Authors:  Roberto Attanasio; Paolo Epaminonda; Enrico Motti; Enrico Giugni; Laura Ventrella; Renato Cozzi; Mario Farabola; Paola Loli; Paolo Beck-Peccoz; Maura Arosio
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

8.  Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.

Authors:  J Ayuk; R N Clayton; G Holder; M C Sheppard; P M Stewart; A S Bates
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

9.  Endonasal transsphenoidal surgery: the patient's perspective-survey results from 259 patients.

Authors:  Joshua R Dusick; Felice Esposito; Carlos A Mattozo; Charlene Chaloner; David L McArthur; Daniel F Kelly
Journal:  Surg Neurol       Date:  2006-04

10.  Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.

Authors:  Pamela U Freda; Abu T Nuruzzaman; Carlos M Reyes; Robert E Sundeen; Kalmon D Post
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958
View more
  3 in total

1.  Effect of rosiglitazone on serum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study.

Authors:  F Bogazzi; G Rossi; M Lombardi; F Raggi; C Urbani; C Sardella; C Cosci; E Martino
Journal:  J Endocrinol Invest       Date:  2010-07-29       Impact factor: 4.256

2.  Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients.

Authors:  V Gasco; G Beccuti; F Marotta; N Prencipe; M Maccario; J Janssen; A J van der Lely; E Ghigo; S Grottoli
Journal:  J Endocrinol Invest       Date:  2011-05-31       Impact factor: 4.256

3.  Meta-analysis on the effects of octreotide on tumor mass in acromegaly.

Authors:  Andrea Giustina; Gherardo Mazziotti; Valter Torri; Maurizio Spinello; Irene Floriani; Shlomo Melmed
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.